Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006198 | Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer | unknown | Phase 2 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00006200 | Thalidomide and Dacarbazine for Metastatic Melanoma | unknown | Phase 2 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00006332 | Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate | completed | Phase 2 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00006433 | Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer | unknown | Phase 2 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00013806 | CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study | unknown | Phase 2 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00022932 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP | unknown | Phase 2 | — | Corixa CorporationINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00022945 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | completed | Phase 2 | — | Corixa CorporationINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00028158 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer | completed | Phase 1 / Phase 2 | 65 | MediGeneINDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
| NCT00034333 | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer | terminated | Phase 2 / Phase 3 | 240 | FeRxINDUSTRY | 8 | Jun 24, 2005 | clinicaltrials |
| NCT00036426 | Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma | unknown | Phase 2 | 22 | FavrilleINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00041808 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | completed | Phase 1 / Phase 2 | 20 | FeRxINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
| NCT00042497 | Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma | suspended | Phase 2 | 60 | AnosysINDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
| NCT00043433 | Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma. | unknown | Phase 2 | 35 | TularikINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
| NCT00043459 | Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma. | terminated | Phase 2 | 35 | TularikINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00048529 | Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus | suspended | Phase 2 | 70 | TularikINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00054951 | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads | unknown | Phase 1 / Phase 2 | 30 | FeRxINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00055562 | Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma | completed | Phase 2 / Phase 3 | 274 | Celgene CorporationINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
| NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | terminated | Phase 2 / Phase 3 | 750 | TularikINDUSTRY | 11 | Jun 24, 2005 | clinicaltrials |
| NCT00057395 | A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 40 | Aronex PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00061126 | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | completed | Phase 2 | 50 | AbgenixINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00081783 | Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients | unknown | Phase 2 | 40 | Xcyte TherapiesINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2005source: clinicaltrials